ImmunityBio Inc (IBRX) concluded trading on Wednesday at a closing price of $3.22, with 5.46 million shares of worth about $17.59 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.61% during that period and on January 22, 2025 the price saw no change. Currently the company’s common shares owned by public are about 696.83M shares, out of which, 75.93M shares are available for trading.
Stock saw a price change of 38.79% in past 5 days and over the past one month there was a price change of 21.51%. Year-to-date (YTD), IBRX shares are showing a performance of 25.78% which decreased to -10.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.28 but also hit the highest price of $10.53 during that period. The average intraday trading volume for ImmunityBio Inc shares is 7.57 million. The stock is currently trading 19.06% above its 20-day simple moving average (SMA20), while that difference is down -14.69% for SMA50 and it goes to -35.06% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 696.83M outstanding shares and institutions hold larger chunk of about 9.44% of that.
The stock has a current market capitalization of $2.35B and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$0.89 in the same period. It has Quick Ratio of 2.64. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 14.44% while standing at 9.15% over the month.
Analysts are in expectations that ImmunityBio Inc (IBRX) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is -0.42 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 30.00% while it is estimated to increase by 16.77% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on January 10, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by Piper Sandler stated ImmunityBio Inc (IBRX) stock as a Neutral in their note to investors on May 12, 2023, suggesting a price target of $4 for the stock.
